跳至主要内容
临床试验/ISRCTN45733939
ISRCTN45733939进行中(未招募)未知

A new combined treatment for post-concussion syndrome: a pilot trial

Durham University0 个研究点目标入组 18 人开始时间: 2022年3月30日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. PCS patients, aged 18 to 64 years. PCS is defined as the persistence of concussion symptoms, for more than 3 months after the initial concussion event
  • 2. Current PCS confirmed by the presence of more than three symptoms on the Rivermead PCS
  • 3. Not using any other pharmaceutical treatment for the management of PCS, e.g. antidepressants
  • 4. Can provide signed informed consent

排除标准

  • 1. Pregnancy
  • 2. Breastfeeding
  • 3. Hepatic insufficiency
  • 4. Renal impairment
  • 5. Any of the following BNF contraindications for cinnarizine: acute porphyrias; epilepsy; Parkinson's disease; prostatic hypertrophy; pyloroduodenal obstruction; susceptibility to angle-closure glaucoma; urinary retention
  • 6. Any of the following BNF contraindications for piracetam: gastric ulcer; history of haemorrhagic stroke; increased risk of bleeding; recent or planned major surgery; underlying disorders of haemostasis; cerebral haemorrhage; Huntington's chorea

研究者

相似试验